PCNA has been proven to be a marker of proliferation in the diagnosis of breast cancer (Juríková et al., 2016), SF3B4 has been shown to be a tumor suppressor, and somatic inactivating mutations occasionally occur in breast cancer (Denu & Burkard, 2017). Here, PCNA is linked to breast carcinoma.